Pfizer AstraZeneca takeover: Insider warns that acquisition could be ‘devastating’ for research

Exclusive: Pfizer’s former head of research slams his old company as it raises its controversial bid for British firm

The row over Pfizer’s £63 billion takeover bid for the British drugs company AstraZeneca intensified last night as the predator’s own former top scientist railed against the way the US firm’s takeovers destroy research teams and stop the creation of new medicines.

Dr John LaMattina’s concerns about the damage his former company’s takeover sprees were doing to medical laboratories around the world fuelled fresh condemnation of the Viagra maker’s assault on AstraZeneca, which employs 7,000 staff in the UK and is a key part of the life sciences industry.

Yesterday, ministers appeared to give the deal their blessing after Pfizer gave assurances that it would not pull the plug on AstraZeneca’s jobs and research plans.

But critics, mindful of how the US food giant Kraft reneged on promises not to close a UK factory after it was allowed to buy Cadbury Schweppes in 2010, remain unconvinced.

Dr LaMattina retired as president of global research and development at Pfizer after 30 years’ service. He later published a paper in the academic journal Nature Reviews Drug Discovery, declaring: “In major mergers today, not only are R&D cuts made, but entire research sites are eliminated. Nowhere is this more evident than with Pfizer.”

Significantly, he said such “devastating” mergers should “be concerning to patients”, as well as doctors, taxpayers and other stakeholders, “particularly bearing in mind recent cutbacks in areas of research such as antibacterial drugs and neuroscience”.

Read more:  The town that Pfizer built up – and knocked down
AstraZeneca investors press for talks after it spurns Pfizer again
AstraZeneca knows there is no room for sentiment as Pfizer circles  

His comments were underlined by leading scientists warning that major takeover deals risked the entire UK life sciences’ premium world status.

“The UK has been a world leader in medicines research and development, but recent closures and restructuring put this position under threat,” chief scientists at the Royal Societies of biology, pharmacology, chemistry and biochemistry warned in a joint open letter.

Former minister Michael Heseltine and Lord Sainsbury also voiced concerns yesterday about the lack of protection for important UK companies from overseas takeover.

Dr LaMattina, who is currently a senior scientist at the US medicine developer PureTech, wrote his article in 2011 but last night told The Independent: “I could have written that article today: the only difference between 2011 is that I’d have more data. If you’re in R&D right now, at either company, you’re going to be worried. In a lot of these acquisitions there are dramatic cuts, and that’s going to happen here as well.”

He predicted drug discovery programmes in their early stages would be disrupted or even abandoned altogether and highlighted AstraZeneca’s divisions looking for cancer treatments as particularly vulnerable.

Yesterday, Pfizer increased its takeover offer price from £60bn to £63bn – or £50 per AstraZeneca share – but the company’s board rejected it as being too low and refused even to meet to discuss the offer. Most shareholders agreed the offer remains too low, but were optimistic that Pfizer can be made to pay more.

Another concern of AstraZeneca’s board was that the bid was driven more by Pfizer’s desire to avoid US taxes than any wider strategic view of the business.

Pfizer admits a main rationale is tax avoidance. The company has a pool of billions of dollars accrued outside the US, which it does not want to bring back to America because of corporation tax on overseas earnings. Spending the money on a takeover means it can avoid the US tax.

But Pfizer says the takeover’s rationale is also about growing the two businesses.

In an open letter to the Prime Minister yesterday, Pfizer’s chief executive Ian Read praised the “golden triangle” for research of Oxford, Cambridge and London, and pledged to complete AstraZeneca’s planned £300m Cambridge campus. At least a fifth of the combined company’s total R&D workforce would be in the UK, he said.

Science minister David Willetts told The Independent these assurances showed the success of the Government’s “hard-nosed and muscular” talks with the US company. He said he and Chancellor George Osborne had both met the Pfizer boss this week, while the Business Secretary, Vince Cable, had spoken with him about his plans for UK jobs and investment .

Mr Willetts acknowledged, however, that some in the science community are concerned.

The Institute of Directors said politicians should stay away from the deal and leave it to shareholders to decide. “It is misleading to present AstraZeneca as some kind of UK national champion… It is run by a Frenchman and chaired by a Swede,” it said.

However, it added that AstraZeneca’s board should take into account concerns about whether a deal based on tax considerations was best for its shareholders.

The Pfizer way: ‘An alarming trend’

In his article criticising the trend for major pharmaceutical mergers, Dr John LaMattina listed the large research centres Pfizer had closed since it began its aggressive spree of takeovers in 1999 – including its controversial closure in 2011 of its hi-tech site in Sandwich, Kent.

“These sites housed thousands of scientists, and many major drugs [including Viagra] were discovered there. The same pattern has been observed after most of the mergers and acquisitions by other major pharmaceutical companies during the past decade,” he wrote.

Dr LaMattina added that the number of new medicines being invented around the world were directly correlated with the number of drug companies operating, saying: “Now, with so many fewer major companies involved in pharmaceutical R&D, the chances of success in the industry overall are likely to be dropping precipitously.”

He cited Pfizer’s takeovers of Warner-Lambert, Pharmacia and Wyeth as well as “multiple smaller companies”.

“Industry consolidation has resulted in less competition and less investment in R&D,” he said. “At a time when there is a major need for new treatments for conditions such as Alzheimer’s disease, drug resistant infections and diabetes, such a trend is alarming.”

PROMOTED VIDEO
Life and Style
Child's play: letting young people roam outdoors directly contradicts the current climate
lifeHow much independence should children have?
Arts and Entertainment
Tycoons' text: Warren Buffett and Bill Gates both cite John Brookes' 'Business Adventures' as their favourite book
booksFind out why America's richest men are reading John Brookes
News
i100
Arts and Entertainment
<p><strong>2008</strong></p>
<p>Troubled actor Robert Downey Jr cements his comeback from drug problems by bagging the lead role in Iron Man. Two further films follow</p>
filmRobert Downey Jr named Hollywood's highest paid actor for second year running
Life and Style
Dale Bolinger arranged to meet the girl via a fetish website
life
Property
Sign here, please: Magna Carta Island
propertyYours for a cool £4m
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Training Programme Manager (Learning and Development)-London

£28000 - £32000 per annum + benefits: Ashdown Group: Training Programme Manage...

Training/Learning and Development Coordinator -London

£28000 - £32000 per annum: Ashdown Group: Training/Learning and Development Co...

Business Anaylst

£60000 - £75000 per annum + BONUS + BENEFITS: Harrington Starr: Business Anal...

Project Manager - ETRM/CTRM

£70000 - £90000 per annum + Job Satisfaction: Harrington Starr: Project Manage...

Day In a Page

Some are reformed drug addicts. Some are single mums. All are on benefits. But now these so-called 'scroungers’ are fighting back

The 'scroungers’ fight back

The welfare claimants battling to alter stereotypes
Amazing video shows Nasa 'flame extinguishment experiment' in action

Fireballs in space

Amazing video shows Nasa's 'flame extinguishment experiment' in action
A Bible for billionaires

A Bible for billionaires

Find out why America's richest men are reading John Brookes
Paranoid parenting is on the rise - and our children are suffering because of it

Paranoid parenting is on the rise

And our children are suffering because of it
For sale: Island where the Magna Carta was sealed

Magna Carta Island goes on sale

Yours for a cool £4m
Phone hacking scandal special report: The slide into crime at the 'News of the World'

The hacker's tale: the slide into crime at the 'News of the World'

Glenn Mulcaire was jailed for six months for intercepting phone messages. James Hanning tells his story in a new book. This is an extract
We flinch, but there are degrees of paedophilia

We flinch, but there are degrees of paedophilia

Child abusers are not all the same, yet the idea of treating them differently in relation to the severity of their crimes has somehow become controversial
The truth about conspiracy theories is that some require considering

The truth about conspiracy theories is that some require considering

For instance, did Isis kill the Israeli teenagers to trigger a war, asks Patrick Cockburn
Alistair Carmichael: 'The UK as a whole is greater than the sum of its parts'

Alistair Carmichael: 'The UK as a whole is greater than the sum of its parts'

Meet the man who doesn't want to go down in history as the country's last Scottish Secretary
Legoland Windsor's master model-makers reveal the tricks of their trade (including how to stop the kids wrecking your Eiffel Tower)

Meet the people who play with Lego for a living

They are the master builders: Lego's crack team of model-makers, who have just glued down the last of 650,000 bricks as they recreate Paris in Windsor. Susie Mesure goes behind the scenes
The 20 best days out for the summer holidays: From Spitfires to summer ferry sailings

20 best days out for the summer holidays

From summer ferry sailings in Tyne and Wear and adventure days at Bear Grylls Survival Academy to Spitfires at the Imperial War Museum Duxford and bog-snorkelling at the World Alternative Games...
Open-air theatres: If all the world is a stage, then everyone gets in on the act

All the wood’s a stage

Open-air productions are the cue for better box-office receipts, new audiences, more interesting artistic challenges – and a picnic
Rand Paul is a Republican with an eye on the world

Rupert Cornwell: A Republican with an eye on the world

Rand Paul is laying out his presidential stall by taking on his party's disastrous record on foreign policy
Self-preservation society: Pickles are moving from the side of your plate to become the star dish

Self-preservation society

Pickles are moving from the side of your plate to become the star dish
Generation gap opens a career sinkhole

Britons live ever longer, but still society persists in glorifying youth

We are living longer but considered 'past it' younger, the reshuffle suggests. There may be trouble ahead, says DJ Taylor